Showing results (1-10 of 228) with videos related to
Sort By:
Pageof 23
Bulletin Du Cancer|March 28, 2025
[Treatment with peri-operative immunotherapy of resectable PCNBs]Mariona Riudavets, Gary Birsen, Jeremy Slomka, et al.JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]Mariona Riudavets, David PlanchardCancer Research and Treatment|November 28, 2024
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?Mariona Riudavets, David PlanchardExpert Opinion on Pharmacotherapy|December 21, 2022
An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancerMariona Riudavets, David PlanchardLung Cancer (Amsterdam, Netherlands)|June 13, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directionsMariona Riudavets, Priscilla Cascetta, David PlanchardCancers|July 9, 2022
Radon and Lung Cancer: Current Trends and Future PerspectivesMariona Riudavets, Marta Garcia de Herreros, Benjamin Besse, et al.La Revue Du Praticien|July 26, 2003
[Bronchoalveolar carcinoma]Marie Wislez, Jacques Cadranel, Bernard MilleronBulletin Du Cancer|November 25, 2015
[Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]Etienne Giroux Leprieur, Vincent Fallet, Marie WislezBulletin Du Cancer|February 11, 2014
[Pulmonary malt lymphoma]Raphaël Borie, Martine Antoine, Jacques Cadranel, et al.Pageof 23